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Abstract
Background: Nowadays, the most common presentation of PCV-2 is the subclinical infection in piglets after
weaning. The success of PCV-2 vaccination is associated with the control of the clinical disease as well as the
improvement of production parameters. In consequence, the objective of the present study was to analyse the
effect of PCV-2 maternally derived antibody (MDA) levels on vaccine efficacy in piglets vaccinated at three weeks of
age with a commercial PCV-2 subunit vaccine. The study was performed analysing a database with 6112 wean-to-
slaughter piglets from 4 different European regions.
Results: Results showed that the use of the vaccine was able to decrease the PCV-2 viremia calculated as area
under the curve (AUC = 60.29 ± 3.73), increase average daily weight gain (ADWG = 0.65 ± 0.01 kg/day) and reduce
mortality (7%) in vaccinated piglets compared to non-vaccinated ones (AUC of 198.27 ± 6.14, 0.62 ± 0.01 kg/day and
11% respectively). The overall difference of ADWG between both groups was close to 30 g per day (p < 0.05), also
when they were split for low and high levels of MDA titres. Moreover, the animals with the highest ADWG were
observed in the group of piglets vaccinated with high or extremely high antibody titres (0.66 and 0.65 kg/day
respectively). Considering only animals with extremely high antibody titres, both study groups performed similar,
however there was a numerical difference of 10 g/day in favour of vaccinated piglets. Likewise, lack of correlation
between ADWG and MDA was observed suggesting that no maternal antibody interference was present with the
tested vaccine because the vaccinated animals grew faster compared to unvaccinated control animals, regardless of
the level of maternal antibodies present at the time of vaccination.
Conclusions: The results of the present study demonstrated that the MDA against PCV-2 transferred through the
colostrum intake has a protective effect against this viral infection. The vaccine used in the present study (Ingelvac
CircoFLEX®) was effective when applied at three weeks of age and was not affected by the level of MDA at the
time of vaccination.
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Background
Porcine circovirus type 2 (PCV-2) has been associated
with a number of clinical conditions in swine that can
cause high economic losses for the pig industry [1, 2].
The most common clinical manifestation of these dis-
eases has been post-weaning multisystemic wasting syn-
drome (PMWS), which was first described in Canada in
1991 [3, 4]. The term porcine circovirus diseases
(PCVDs) has been used to compile all conditions linked
to PCV-2 [5], and subsequently these clinical syndromes
were reviewed and some new names proposed [6]. Now-
adays the most common presentation of PCV-2 is the
subclinical infection (PCV-2-SI) in piglets after weaning.
Other described syndromes are: PCV-2 systemic disease
(PCV-2-SD, the former PMWS) [7–9], PCV-2 lung dis-
ease (PCV-2-LD), PCV-2 enteric disease (PCV-2-ED)
[10–13], PCV-2 reproductive disease (PCV-2-RD) [14–
16] and porcine dermatitis and nephropathy syndrome
(PDNS) [17]. However, PCV-2-LD and PCV-2-ED have
been considered as negligible conditions, since the virus
linked with lung and intestine inflammation is usually
found within the framework of PCV-2-SD [18, 19].
The success of PCV-2 vaccination is associated with
the control of the clinical disease as well as prevention
of tissue lesions [1, 20–23]. Even when no overt clinical
signs are observed in PCV-2-SI scenarios, several field
studies have demonstrated that PCV-2 piglet vaccination
is able to improve production parameters [average daily
weight gain (ADWG)], percentage of runts, body condi-
tion and carcass weight) [24]. In consequence, the use of
vaccination in farms with clinical PCVD and PCV-2-SI
has shifted the general pig health from a period of
worldwide severe clinical outbreaks (1997–2007) to self-
limiting subclinical infections with occasional outbreaks.
In this widespread vaccination scenario in piglets and
the increasing use of PCV-2 vaccines in sows, the mater-
nally derived antibody (MDA) levels and their potential
interference with vaccines applied in their offspring [25]
might pose a risk to vaccination efficacy. Therefore, it
may be necessary to refine the vaccination timing sched-
ules commonly established around weaning for piglets.
Different laboratory tests may be used for the detec-
tion of PCV-2 antibodies in serum. Therefore, serology
can be regarded as a useful tool for monitoring presence
of antibodies in pigs and sows, and potentially assess
their levels at the time of vaccination. Traditionally, the
IPMA (immunoperoxidase monolayer assay) method has
been used to detect PCV-2 antibodies quantitatively.
However, Guedes et al. [26] showed that the IFAT (in-
direct fluorescence antibody test) method for the diag-
nosis of the porcine proliferative enteropathy was able to
offer very similar values to the IPMA (98,6% of agree-
ment). PCV-2 antibody levels have been described to be
moderate to high in piglets when above 1:320 or its
equivalent 2.5 log10 using indirect fluorescence antibody
titration (IFAT) [27].
The objective of the present study was to analyse the
effect of PCV-2 MDA levels on vaccine efficacy (mea-
sured by ADWG and PCV-2 viremia) in piglets vacci-
nated at three weeks of age with a commercial PCV-2
subunit vaccine. The study was performed in four differ-
ent farms in Europe.
Results
Descriptive analysis of the effect of vaccination
The first objective was to analyse the effect of the vac-
cine on each of the parameters studied independently
(Fig. 1). The mean ADWG was significantly higher in
the vaccinated animals (0.65 ± 0.01 kg/day) compared
with the placebo-treated animals (0.62 ± 0.01 kg/day),
corresponding to an overall ADWG difference between
the groups of 30 g per day (Fig. 1a; p < 0.05). The same
result was observed in all farms used in this study; in all
of them ADWG was significantly higher in the vacci-
nated animals (Table 1; p < 0.05), with a range of ADWG
differences between groups between 20 and 50 g per day.
Fig. 1 Effect of vaccination on average daily weight gain (ADWG), PCV-2 viral load (represented as area under curve-AUC) and PCV-2 antibody titre. a)
Comparison of the average daily weight gain (ADWG, kg/day) in placebo-treatment (n = 2728) and vaccinated animals (n = 2835), b) comparison of
the PCV-2 viral load as area under curve (AUC) in placebo-treatment (n = 484) and vaccinated animals (n = 472) and c) comparison of the PCV-2
antibody titre (log10) in placebo-treatment (n = 2728) and vaccinated animals (n = 2835). Different letters (a, b) indicate significant differences (P < 0.05)
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The mean value of area under the curve (AUC) in vac-
cinated animals (60.29 ± 3.73) was significantly (p < 0.05)
lower than that of unvaccinated animals (198.27 ± 6.14).
The profile of PCV-2 viral load as AUC at the end of the
study is illustrated in Fig. 1b. The overall AUC in vacci-
nated animals was 3.3 times lower than that of placebo-
treated animals (p < 0.05).
MDA titres were determined from all animals the day
of vaccination. Prior to vaccination PCV-2 antibody ti-
tres of both treatment groups were statistically equal in
both study groups with a mean geometric value of 2.7
log10 (Fig. 1c; p > 0.05). The same result was observed in
all farms used in this study; in all of them MDA was sig-
nificantly similar in the vaccinated animals vs. placebo-
treated animals (Table 2; p > 0.05).
Average daily weight gain (ADWG) according to MDA
This analysis was done in order to investigate whether
the presence of MDA against PCV-2 had any influence
on the efficacy of vaccination, in terms of average daily
weight gain (ADWG). Figure 2 shows the ADWG de-
pending on the MDA titres in vaccinated and placebo-
treated animals. No significant correlation (p > 0.05) was
observed between these two variables for both treatment
groups.
The levels of MDA recorded for all animals on the day
of inclusion (3 weeks of age), were used to evaluate the
distribution of antibody levels in the study population.
The animals were split in low (< 2.5 log10), high (≥2.5
log10) and extremely high (≥3.7 log10) PCV-2 titres at
the time of vaccination. Figure 3 shows a lack of correl-
ation between ADWG and MDA of vaccinated or non-
vaccinated animals according to this grouping (p > 0.05).
When the ADWG was analysed comparing vaccinated
and non-vaccinated animals for low (< 2.5 log10) and
high (≥2.5 log10) PCV-2 antibody titres at vaccination
(Table 3), ADWG was significantly higher in the vacci-
nated animals vs the control ones for both groups (low:
0.64 vs. 0.61 kg/day, respectively; high: 0.66 vs. 0.62 kg/
day, respectively; p < 0.05). In contrast, no significant
differences (p > 0.05) were found between the experi-
mental groups (vaccinated vs non-vaccinated) after ana-
lysing the population of animals with extremely high
PCV-2 antibody titres (≥3.7 log10). However, a numerical
difference (10 g) was observed in favour of vaccinated
animals (0.65 vs. 0.64 kg/day, respectively) and it must
be taken into account the low number of animals in this
group that decreases significantly the statistical potency.
It is important to note that for both study groups the
lowest levels of ADWG appear in the group of low
PCV-2 antibody titres.
After analysing the ADWG for the different levels of
PCV-2 antibody titres (low, high and extremely high) in
each one of the study groups (placebo vs. vaccinated ani-
mals), it is observed that in the case of the placebo animals
there are statistical differences between all the levels (0.61,
0.62 and 0.64) whereas in the vaccinated animals only stat-
istical differences appear between the low level and the
rest, there being no differences between the somewhat
high and extremely high levels (0.66 vs. 0.65).
Because of these results, two further analyses were car-
ried out to evaluate in depth the group of extremely high
antibody titres. For the first one, those animals with PCV-
2 antibody titres ≥4.31 log10 (highest antibody titres) were
compared for both study groups (placebo-treatment n =
158 and vaccinated animals n = 163), without finding sig-
nificant differences between them (p > 0.05). For the sec-
ond analysis, animals with highest antibody titres (≥4.31
log10; n = 163) were compared to animals with lowest anti-
body titres (≤1.90 log10; n = 202) and only within the vac-
cinated group finding numerically superior (10 g; p > 0.05)
differences for the highest antibody titre group.
PCV-2 AUC level according to MDA
When de AUC was analysed for the different levels of
PCV-2 antibody titres (low, high and extremely high) in
each one of the study groups (placebo vs. vaccinated ani-
mals) (Table 4), it is observed that in the case of the pla-
cebo animals only statistical differences appear between
low and extremely high levels (225.0 vs. 147.6) whereas in
Table 1 Mean of ADWG (kg/day) ± SEM for each of the four studies analysed
Treatment Southern Germany [1] Northern Germany [28] United Kingdom [29] France [30]
Placebo animals (n = 2728) 0.61 ± 0.01 a (n = 654) 0.65 ± 0.01 a (n = 706) 0.56 ± 0.01 a (n = 657) 0.66 ± 0.01 a (n = 711)
Vaccinated animals (n = 2835) 0.64 ± 0.01 b (n = 677) 0.67 ± 0.01 b (n = 718) 0.61 ± 0.01 b (n = 718) 0.68 ± 0.01 b (n = 722)
ADWG difference between groups (g/day) 30 20 50 20
n: number of animals. a,b Different letters in the same column indicate significant differences (p < 0.05). Only the surviving animals per treatment group were used
Table 2 Mean of MDA (PCV-2 antibody titre (log10)) ± SEM for each of the four studies analysed
Treatment Southern Germany [1] Northern Germany [28] United Kingdom [29] France [30]
Placebo animals (n = 2728) 2.80 ± 0.03 (n = 654) 2.87 ± 0.03 (n = 706) 2.42 ± 0.02 (n = 657) 2.56 ± 0.02 (n = 711)
Vaccinated animals (n = 2835) 2.83 ± 0.03 (n = 677) 2.86 ± 0.03 (n = 718) 2.39 ± 0.02 (n = 718) 2.60 ± 0.02 (n = 722)
n: number of animals. No significant differences found (p > 0.05). Only the surviving animals per treatment group were used
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the vaccinated animals no differences were found between
the different levels (63.4, 55.4 and 75.5). After comparing
the study groups for each of the antibody levels, it is ob-
served that in all cases the viremia is statistically higher
for the placebo animals compared to the vaccinated ani-
mals (low: 225.0 vs. 63.4; high: 188.5 vs. 55.4 and ex-
tremely high: 147.6 vs. 75.5, respectively; p < 0.05).
Average daily weight gain (ADWG) according to PCV-2
AUC level
A significant (p < 0.05) negative correlation (R = −
0.3748) between ADWG and AUC (Fig. 4) was observed
for non-vaccinated pigs. Thus, the higher the PCV-2
AUC viremia, the lower the ADWG. This correlation
was not observed in vaccinated population (p = 0.06).
Mortality
The mortality within vaccinated animals was always
lower than in control animals at farm level, showing
statistical significant differences in two of the studies
(p < 0.05) (Table 5). Moreover, merging data from the
four studies, the mortality in vaccinated animals was sig-
nificantly lower than in placebo pigs (7% vs. 11%, re-
spectively; p < 0.05) (Table 5). However, it was not
observed a significant association between PCV-2 MDA
and mortality between farms.
a) b)
Fig. 2 Bivariate adjustment between the average daily weight gain (ADWG) and the PCV-2 antibody titre. Graphs show dates for placebo-
treatment (n = 2728) a) and vaccinated (n = 2835) animals b). The ADWG of each animal was calculated as the difference in body weight
between two measurement periods (4 and 25 weeks of age) divided by the number of days between them
a) b) c)
d) e) f)
Fig. 3 Bivariate adjustment between average daily weight gain (ADWG) and PCV-2 antibody titre divided by PCV-2 titres. Graphs show dates for
placebo-treatment (n = 2728) and vaccinated animals (n = 2835). Analysis divided by PCV-2 titres a) placebo low titre (< 2.5 log10; n = 811), b)
placebo high titre (≥2.5 log10; n = 1917), c) placebo extremely high titre (≥3.7 log10; n = 300), d) vaccinated low titre (< 2.5 log10; n = 877), e)
vaccinated high titre (≥2.5 log10; n = 1958) and f) vaccinated extremely high titre (≥3.7 log10; n = 334)
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Discussion
At the beginning of the 90s, PCV-2-SD emerged as a
new swine disease, which was characterized by wasting,
a strong reduction of ADWG and high mortality,
appearing mainly between 5 and 12 weeks of life [7, 31].
Moreover, the disease caused an increase in the cost of
production not only due to mortality and loss of
ADWG, but also due to an increase of medication costs
and the number of animals with no commercial value
[32]. As a consequence, a loss of profitability was ob-
served in affected farms. However, the advent of PCV-2
vaccines by late 2000s demonstrated that the disease is
able to be counteracted, and further benefits come from
the prevention of subclinical infections [33].
Antibodies of maternal origin are present in all piglets
if appropriate colostrum intake takes place [34]; such
antibodies in serum gradually decrease during the phases
of lactation and nursery [35]. PCV-2 viremia usually ap-
pears between the final phase of nursery and the start of
the fattening phase, coinciding with the time when
MDA reach minimum levels [36, 37], and suggesting
therefore that MDA confer some protection against the
development of the disease.
Since the very beginning, piglet vaccination was
proven to be highly efficacious to control PCV-2-SD as
well as PCV-2-SI [28]. However, taking into account that
vaccination takes place in presence of maternally derived
immunity, the potential interference of MDA with vac-
cine efficacy has to be considered. Interference with ma-
ternal antibodies could be vaccine dependent as the
different vaccines available on the market are based on
different antigen expression systems and also differ in
antigen quantity, purity, and adjuvants. As a working hy-
pothesis, it was expected that the vaccine used in the
present study might be less effective in animals with
“high” MDA titres. However, the vaccine proved to be
effective regardless of the level of maternal antibodies
present at the time of vaccination. In consequence, the
used vaccine was able to overcome usual levels of MDA,
decrease the viremia loads and increase ADWG com-
pared to non-vaccinated piglets [20, 28], with an overall
difference of ADWG between groups of 30 g per day
both for low and high levels of MDA titres. Moreover,
according to obtained results, a maternal antibody inter-
ference with the efficacy of the tested vaccine was not
observed, since irrespective of the maternal antibody
level present at the time of vaccination, the vaccinated
animals grew faster compared to the non-vaccinated
control animals.
Likewise, the application of the vaccine was able to re-
duce mortality in vaccinated animals. However, it was
not observed a significant association between PCV-2
MDA and mortality between farms, probably because
the mortality was due to many factors (infectious and
non-infectious ones) and the maternally immunity
against PCV2 is only one of them.
The interference of the maternally transferred immun-
ity (MDI) against any vaccine can be described as a
blocking of the antigen by the circulating antibodies or
by other components, presumably cell mediated, ac-
quired through colostrum. This is well understood for
other swine infectious diseases like Aujeszky Disease
virus (ADV) [38], Classical Swine Fever virus [39], Influ-
enza A virus (IAV) [40] or Swine Parvovirus [41]. For
example, pigs with significant IAV-specific MDA titres
can have suppressed adaptive antibody responses to
homologous infection or vaccination [40, 42]. For both
IAV and ADV evidence suggests that the cellular im-
mune response appears to be less susceptible to MDA
[43]. The impact of MDA on active immunisation with
PCV2 vaccines in young pigs has been studied previously
[44–46]. One of these studies found that under the
Table 3 Mean of ADWG (kg/day) for placebo and vaccinated animals according to the levels of PCV-2 antibody titre
PCV2 titre Placebo animals (n = 2728) Vaccinated animals (n = 2835)
Low titre (< 2.5 log10) 0.61
a,A (n = 811) 0.64 a,B (n = 877)
High titre (≥2.5 log10) 0.62
b,A (n = 1617) 0.66 b,B (n = 1624)
Extremely high titre (≥3.7 log10) 0.64
c,A (n = 300) 0.65 b,A (n = 334)
a,b,c Different letters in the same column indicate significant differences (p < 0.05)
A, B Different letters in the same row indicate significant differences (p < 0.05). Only the surviving animals per treatment group were used
Table 4 Mean of area under the curve (AUC) of PCV2 load over time for placebo and vaccinated animals according to the levels of
PCV-2 antibody titre
PCV2 titre Placebo animals (n = 472) Vaccinated animals (n = 484)
Low titre (< 2.5 log10) 225.0 a,A (n = 169) 63.4 a,B (n = 173)
High titre (≥2.5 log10) 188.5 ab,A (n = 265) 55.4 a,B (n = 262)
Extremely high titre (≥3.7 log10) 147.6 b,A (n = 38) 75.5 a,B (n = 49)
a,b Different letters in the same column indicate significant differences (p < 0.05)
A, B Different letters in the same row indicate significant differences (p < 0.05). Only 15% of randomly pre-selected study animals, chosen as representative sample
animals, were used
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conditions of that trial that age of vaccination rather
than MDA influenced the efficacy of PCVD control. The
authors concluded that PCV2 vaccination in the pres-
ence of high MDA levels is efficacious when used in 3-
week old but not in 1-week old pigs, suggesting that vac-
cine efficacy was independent of the level of MDA. The
authors speculated that other age-related factors may
have interfered with the efficacy of the vaccine in 1-week
old piglets [44]. Another study using a different PCV2
vaccine found that while interference at the very highest
MDA titres could not be excluded the authors con-
cluded that under field conditions this impact is prob-
ably negligible [46]. The MDA interference effect could
result in a lack of passive immunity but also a lack of ac-
tive immunisation resulting in worst growing perform-
ance of the animals when challenged. In one study with
high titres in sows induced by vaccination, it was con-
cluded that some interference of MDA on the induction
of an efficient immune response should be considered
[45]. They concluded that an optimal PCV2 vaccination
strategy needs to balance the levels of passive immunity,
the management practices and timing of infection. Con-
trary to this statement, this study shows that the pigs
that had superior ADWG were those that presented high
or very high MDA titres at the time of vaccination (low:
0.64; high: 0.66 and extremely: 0.65 kg/day). This obser-
vation differs slightly with the results obtained by Feng
et al. [46] where the low and high MDA vaccinated pig-
lets (n = 78 and 93 respectively) grew equally. This dif-
ference could be explained by the size of the groups
between both studies. However, the results obtained in
the present study could be due to the fact that high titers
of antibodies mean high level of protection to the field
virus challenge [47]. These animals had an apparent
double protection, the one provided by their own high
MDA (passive immunity) and the one by vaccination
(active immunity which overcomes mostly MDA). It is
very likely that, in these circumstances, the antibody
levels remain fairly high during the whole life of the ani-
mal and, therefore, protected against the natural
challenge.
The piglets with a huge amount of antibodies at time
of vaccination (≥4.31 log10) showed the same or even
numerically better growth (10 g; p > 0.05) than those ani-
mals with the lowest amount of circulating antibodies
(≤1.90 log10). This fact suggests that the vaccine antigen
was not neutralized by MDA even in the highest anti-
body concentrations, reducing the likelihood of sus-
pected interference. This observation is in line with the
results obtained in the Feng et al. [46] study where 10
animals with extremely high MDA were compared to
157 animals with a lower MDA showing no statistical
differences in growth.
On the other hand, the present study also shows that
in the unvaccinated population the pigs that grew more
were those that presented high or very high MDA titres
(low: 0.61; high: 0.63 and extremely: 0.64 kg/day) sup-
porting the fact that MDI can provide some degree of
protection. Similar results were found in the Feng et al.
study [46]. In the case of the groups with extremely high
Fig. 4 Bivariate adjustment between the average daily weight gain (ADWG) and the viraemia (represented as area under curve-AUC). Graphs
show dates for a) placebo-treatment (n = 472) and b) vaccinated animals (n = 484)
Table 5 Percentage of mortality for each of the four studies analysed and for the merged data
Treatment Southern Germany [1] Northern Germany [28] United Kingdom [29] France [30] Merged data
Placebo animals (%) 14 a 9 15 a 6 11 a
Vaccinated animals (%) 10 b 7 5 b 5 7 b
a,b Different letters in the same column indicate significant differences (p < 0.05). Merged data refers to the grouping of animals of all the farms studied
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and highest MDA (≥ 3.7 and ≥ 4.31 log10 respectively),
no statistical differences in ADWG were observed be-
tween the vaccinated and non-vaccinated animals. It
must be taken into account the low statistical power in
these groups selected for extremely high MDA.
These observations reinforce the fact that the MDA
transferred through the intake colostrum has a protective
effect against PCV-2 infection. Similar results were found
in previous studies using the same vaccine used in the
present trial [46, 48]. While a vaccine effect in relation to
ADWG could not be statistically demonstrated in this
sub-population of pigs receiving extremely high MDA, it
is also true that no conclusive evidence of interference
could be determined. In the case of unvaccinated animals
with very and highest MDA titres, they appear to be more
protected against PCV-2 and therefore a good growth per-
formance was observed in these groups. The results ob-
tained could be explained by a better early protection in
these animals [36] due to the presence of some type of im-
mune factor from colostrum beside antibodies such as
lymphocytes, cytokines [34], which could contribute to a
better basal immunity. On the other hand, the effect could
be confounded by the broad benefit that high intake of
colostrum confers to piglets during their whole life [49].
This small sub-population of piglets receiving extremely
high MDA might not need an active immunization against
PCV2 in the context of a well-protected herd.
However, under a practical vaccination approach,
where we cannot determine the MDA status of every pig
and cannot assume immunity, the entire piglet popula-
tion should be vaccinated to ensure homogeneous and
full protection. Furthermore, these results may support
the vaccination of sows since generating high MDA [50]
would protect piglets from early infection and would not
interfere with active immunization against PCV-2. The
present data supports that vaccination against PCV-2 re-
sults in a significant reduction in piglet viraemia irre-
spective of the initial MDA status, which confirms the
positive effect of vaccination. Non-vaccinated animals
had higher AUC of viral load and lower ADWG com-
pared to vaccinated ones, which is in accordance with
what has been obtained in recent study [48].
Conclusions
The results of the present study demonstrated that the effi-
cacy (in terms of ADWG improvement and viraemia) of the
vaccine used in the present study (Ingelvac CircoFLEX®),
when applied at 3 weeks of age to control PCV-2, was not
affected by the level of MDA at the time of vaccination.
Materials and methods
Farm description and situation
The present study was performed using data from four
field trials conducted in different locations of Europe
(southern and northern of Germany [1, 28], United
Kingdom [29] and France [30]). A total of 6112 conven-
tional commercial (1514 southern and 1542 northern of
Germany; 1536 United Kingdom and 1520 France)
cross-bred piglets from non-vaccinated sows against
PCV-2 were used in this work.
These four studies were conducted 10 years ago
when the disease was in the epizootic phase, so the
farms got infected approximately at the same time
and clinical signs were observed and PCV-2-systemic
disease diagnosed according accepted criteria. In three
studies [1, 29, 30] a consistent PCV-2 systemic dis-
ease (PCV-2 SD) with wasting as a major clinical sign
was described. In the other study [28], most of the
clinical signs were respiratory, but PCV-2-systemic
disease was also diagnosed.
Test articles
An inactivated subunit vaccine (Ingelvac CircoFLEX®,
Boehringer Ingelheim Vetmedica GmbH) was adminis-
tered at three weeks of age for immunization against
PCV-2. The vaccine contained the ORF2 capsid protein
of PCV-2 as active component and an aqueous polymer
(carbomer) as adjuvant. This protein has been identified
as the major immunogenic antigen of PCV-2 inducing a
protective response [51, 52]. The ORF2 sequence was
subsequently inserted into a baculovirus expression sys-
tem using an insect cell line derived from ovaries of the
armyworm Sodoptera frugiperda (SF+ cells) as host. The
placebo control consisted of insect cell culture super-
natant without PCV-2 capsid protein but containing car-
bomer adjuvant.
Study design
All 4 field trials were performed according to the princi-
ples of “Good Clinical Practice” (GCP) and followed a
randomized, negative-controlled, double-blinded, parallel
study design. All piglets enrolled into the field studies
received a single dose (1 mL) of the PCV-2 vaccine
Ingelvac CircoFLEX® (vaccine) or aqueous polymer adju-
vant cell culture supernatant (placebo) by intramuscular
injection into the neck around weaning (2 to 3 weeks of
age). Weaning and transfer to the nurseries were per-
formed the day after vaccination (2 to 3 weeks of
age); pigs were transferred to the fattening units at 9
weeks of age. All animals (vaccinated or not) were
kept under conventional housing conditions and were
mixed in pens to ensure that all study pigs were
housed in similar conditions, received the same feed
and were subjected to the same management prac-
tices. At each location change, animals were newly
mixed and randomly assigned to the pens according
to the usual farm procedure.
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Sample collection and study parameters
Blood samples were collected on the day of inclusion
from all piglets, coinciding with the moment of weaning
(2 to 3 weeks of age), and prior to injection (vaccine or
placebo) to determine the presence of PCV-2 antibodies
acquired from maternal colostrum (PCV-2 titre). All ani-
mals were also individually weighed at inclusion and be-
fore slaughter (about 3 and 25 weeks of age). Only data
from live/ear-tagged animals at the end of the study
were used to carry out further analysis (5563 animals
[91%]; 2835 and 2728 from vaccinated and control
groups, respectively).
For quantification of PCV-2 viremia, blood samples
from 15% of randomly pre-selected study animals, chosen
as representative sample animals (total of 956 piglets; 484
from the vaccinated group and 472 from the control
group), were collected on weekly or bi-weekly basis
throughout the study period.
PCV-2 maternally derived antibody (MDA) titre
Quantification of the titre of anti-PCV-2 antibodies in
porcine serum samples from the first blood sampling
was performed at bioScreen GmbH (Münster, Germany),
using an indirect fluorescence antibody titration (IFAT)
assay. Briefly, 2–6 × 104 PCV-2 susceptible cells (VIDO-
R1 cells [53, 54]) were seeded onto a 96-well plate at 2–
6 × 104 cells/well, and inoculated with PCV-2 virus (104.5
TCID50/well) for approximately 48 h. After fixation of
the cells with ethanol, serial dilutions of porcine serum
samples were added to the plates in triplicate and incu-
bated for 1 h at 37 °C, allowing antibodies to bind if
present in the sera. Plates were washed and stained for
1 h at 37 °C with a goat-anti-swine FITC-labelled anti-
body (Dianova, Germany, #114–095-003), which allowed
antigen detection in infected cells using fluorescence mi-
croscopy. The plates were read by an independent
blinded investigator and individual wells reported as
positive or negative. Serum antibody titres were calcu-
lated by the method of Reed and Muench using the
highest dilution still showing specific IFAT reactivity
and the number of positive wells per dilution. The
method allowed the detection of antibody titres in a
range from 1:5 to 1:20480. For the analysis of MDA ti-
tres against PCV-2, the data were transformed to base
10 logarithm (log10) [25]. As indicated above a total of
5563 animals were used (2835 and 2728 from vaccinated
and control groups, respectively).
According to the MDA titre results (those from the
first sampling at 2 to 3 weeks of age), the animals were
classified into two different groups: “high” (≥2.5 log10)
and “low” (< 2.5 log10) at the time of vaccination. In
addition, a third group was established including the
10% of the piglets with the highest antibody titres, whose
limit was established by the 90th percentile (≥3.7 log10).
Average daily weight gain (ADWG)
Weight gain was established as a primary parameter of
efficacy. Average daily weight gain (kg/day) of each ani-
mal was calculated as the difference between the body
weights of two weighing time points divided by the
number of days between these two weighing time points.
For each of the four trials analysed, the mean of ADWG
was performed on the basis of the ADWG of only the
surviving animals per treatment group. In the same way
the mean ADWG was calculated using all the data as a
single set. As indicated above, a total of 5563 animals
were used (2835 and 2728 from vaccinated and control
groups, respectively).
PCV-2 viral load in serum
Quantification of the PCV-2 viral load in serum was per-
formed at bioScreen GmbH, (Münster, Germany). Sam-
ples were analysed in triplicate by a real-time
polymerase chain reaction method as described previ-
ously [55]. PCV-2 DNA quantification was achieved by
comparison of the unknown sample with a standard
curve derived from known amounts of PCV-2 ORF plas-
mid DNA (104–1012 copies/ml, 10- fold dilution steps)
and the cut-off level for a positive sample was set as 104
template copies per millilitre serum based on validation
experiments.
Analysis of PCV-2 viremia parameters
The mean viral load for each piglet was calculated as the
arithmetic mean of individual viral loads (genomic
equivalents (gE)/ml of serum) of each sampling day.
Only animals that could consistently be followed over
the course of the study were included in this calculation
(surviving pigs at the end of the study samples from 15%
of randomly pre-selected study animals (total of 956 pig-
lets; 484 from the vaccinated group and 472 from the
control group).
For a better understanding of the viraemia dynamics
in the present study, PCV-2 qPCR data were also ana-
lysed using the area under the curve (AUC), as an indi-
cator of the viral load over the time of this study. AUC
was calculated using the time of sampling and the PCV-
2 viral load quantified using the trapezoidal method, as
previously described [47]. In order to analyse differences
between study groups, the mean value of AUC was cal-
culated for each of the populations.
Mortality
Dead animals during the study in each of the farms were
registered by the staff of the same. For each animal, their
identification number was recorded as well as the date
of death or withdrawal from the study.
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Statistical analyses
All statistical analyses were carried out using the SAS
system V.9.1.3 (SAS institute Inc., Cary, NC, USA). For
all analyses, the individual pig was considered as the ex-
perimental unit. The farm was included as a variable in
the analysis. The significance level (α) was set at 0.05.
Evaluation of the efficacy of the vaccination protocol
A basal homogeneity analysis was performed to verify
that the treatment groups were balanced by sex and
weight prior the beginning of the trial. Parameters
ADWG, AUC and mortality were analysed for assump-
tion of normality and homogeneity of variances using
the Kolmogorov-Smirnov and Levene test, respectively.
Differences between groups for ADWG, AUC and mor-
tality were compared using an ANOVA test for normally
distributed variables and Kruskall-Wallis test for non-
normally distributed ones.
Maternally derived antibody effects on ADWG
A linear regression was performed to evaluate the
strength of association between the PCV-2 antibody titre
at the day of vaccination for vaccinated and control pig-
lets and the ADWG during the whole rearing period
(from 4 to 25 weeks of age). Moreover, a similar linear
regression analysis was performed for vaccinated piglets
but splitting the animals in low (< 2.5 log10), high (≥2.5
log10) and extremely high (≥3.7 log10) PCV-2 titres, as
described above.
Maternally derived antibody effects on viremia (PCV-2 AUC)
Differences between groups (placebo-treatment and vac-
cinated animals) for AUC were performed splitting the
animals in low (< 2.5 log10), high (≥2.5 log10) and ex-
tremely high (≥3.7 log10) PCV-2 titres, as described
above.
PCV-2 AUC effects on ADWG
A linear regression was performed to evaluate the
strength of association between the PCV-2 AUC for vac-
cinated and control piglets and the ADWG during the
whole rearing period (from 4 to 25 weeks of age).
Abbreviations
ADWG: Average daily weight gain; AUC: Area under the curve; IAV: Influenza
A virus; IFAT: Indirect fluorescence antibody test; IPMA: Immunoperoxidase
monolayer assay; MDA: Maternally derived antibody; MDI: Maternally
transferred immunity; PCV-2: Porcine circovirus 2; PCV-2-ED: Porcine
circovirus 2 enteric disease; PCV-2-LD: Porcine circovirus 2 lung disease; PCV-
2-RD: Porcine circovirus 2 reproductive disease; PCV-2-SD: Porcine circovirus
2 systemic disease; PCV-2-SI: Porcine circovirus 2 subclinical infection;
PCVDs: Porcine circovirus diseases; PDNS: Porcine dermatitis and
nephropathy syndrome; PMWS: Post-weaning multisystemic wasting
syndrome; SEM: Standard error of the mean
Acknowledgements
We are grateful to Richard Evans and Claire Phythian from Bishopton
Veterinary Group, Ripon, North Yorkshire, England, for their help conducting
this study. J-P Denotte from Clinique vétérinaire Faubourg de Châlons, Vitry
Le François, France. We are grateful to the staff of the Clinic for swine, Lud-
wig Maximilians University, Munich, Germany for their support in collecting
blood samples and weighing animals. We also acknowledge Prof. Dr. Thomas
Blaha and the personnel of the Aussenstelle fur Epidemiologie, Bakum,
Germany for necropsy and collection of organ samples. We are grateful to
Christiane Fetzer, Christoph Keller, Volker Ohlinger and the technical staff of
bioScreen GmbH, Münster, Germany for PCR and serologic analyses. Finally,
we thank the pig farmers for their cooperation.
Authors’ contributions
SF-G contributed to the design of the study, analysed the data and wrote
the draft of the paper. LF analysed the data and wrote the draft of the
paper. JS wrote the draft of the paper. IH-C contributed to the design of the
study. RL-Ú analysed the data and wrote the draft of the paper. FAG-V con-
tributed to the design of the study. OG-D wrote the draft of the paper. BG-L
conceived and designed the experiments. All authors read and approved the
final manuscript.
Funding
Not applicable.
Availability of data and materials
Not applicable.
Ethics approval
The field trials were carried out in strict accordance with the
recommendations in the Good Clinical Practice Guidance Document (VICH
GL9). The protocols were developed following the Legislation for the
protection of animals used for scientific purposes (Directive 2010/63/EU) and
all efforts were carried out to minimize suffering.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Physiology, Faculty of Veterinary, Campus Mare Nostrum,
University of Murcia, 30100 Murcia, Spain. 2IMIB-Arrixaca, Murcia, Spain.
3Departamento de Ciencia Animal, Universidad de Lleida, Lleida, Spain.
4Departament de Sanitat i Anatomia Animals, Facultat de Veterinària,
Universitat Autònoma Barcelona, 08193 Bellaterra, Spain. 5UAB, Centre de
Recerca en Sanitat Animal (CRESA, IRTA-UAB), Campus de la Universitat
Autònoma de Barcelona, 08193 Bellaterra, Spain. 6Department of Cell Biology
and Histology, Faculty of Medicine, Campus Mare Nostrum, University of
Murcia, 30100 Murcia, Spain. 7Boehringer Ingelheim Vetmedica GmbH AH
Swine, Ingelheim, Germany.
Received: 2 May 2019 Accepted: 16 July 2019
References
1. Kixmöller M, Ritzmann M, Eddicks M, Saalmüller A, Elbers K, Fachinger V.
Reduction of PMWS-associated clinical signs and co-infections by
vaccination against PCV2. Vaccine. 2008;26(27):3443–51.
2. Horlen KP, Schneider P, Anderson J, Nietfeld JC, Henry SC, Tokach LM, et al.
A cluster of farms experiencing severe porcine circovirus associated disease:
clinical features and association with the PCV2b genotype. Journal of Swine
Health and Production. 2007;15(5):270–8.
3. Clark E. Pathology of the post-weaning multisystemic wasting syndrome of
pigs. Proc Western Can Assoc Swine Pract. 1996.
4. Harding J. Post-weaning multisystemic wasting syndrome: preliminary
epidemiology and clinical findings. Proceedings West Can Association of
Swine Practitioners. 1996;1996:21.
5. Allan G, Krakowka S, Ellis J. PCV2: ticking time bomb. Pig Progress. 2002;18:
14–5.
6. Segalés J. Porcine circovirus type 2 (PCV2) infections: clinical signs,
pathology and laboratory diagnosis. Virus Res. 2012;164(1):10–9.
Figueras-Gourgues et al. Porcine Health Management            (2019) 5:21 Page 9 of 11
7. Harding JC, Clark EG. Recognizing and diagnosing postweaning multisystemic
wasting syndrome (PMWS). Swine Health Prod. 1997;5(5):201–3.
8. Krakowka S, Ellis J, McNeilly F, Meehan B, Oglesbee M, Alldinger S, et al.
Features of cell degeneration and death in hepatic failure and systemic
lymphoid depletion characteristic of porcine circovirus-2–associated
postweaning multisystemic wasting disease. Vet Pathol. 2004;41(5):471–81.
9. Rosell C, Segalés J, Plana-Duran J, Balasch M, Rodrıguez-Arrioja G, Kennedy
S, et al. Pathological, immunohistochemical, and in-situ hybridization studies
of natural cases of postweaning multisystemic wasting syndrome (PMWS) in
pigs. J Comp Pathol. 1999;120(1):59–78.
10. Harms PA, Halbur PG, Sorden SD. Three cases of porcine respiratory disease
complex associated with porcine circovirus type 2 infection. Journal of
Swine Health and Production. 2002;10(1):27–30.
11. Kim J, Chung H-K, Chae C. Association of porcine circovirus 2 with porcine
respiratory disease complex. Vet J. 2003;166(3):251–6.
12. Kim J, Ha Y, Jung K, Choi C, Chae C. Enteritis associated with porcine
circovirus 2 in pigs. Can J Vet Res. 2004;68(3):218–21.
13. Opriessnig T, Meng X-J, Halbur PG. Porcine circovirus type 2–associated
disease: update on current terminology, clinical manifestations,
pathogenesis, diagnosis, and intervention strategies. J Vet Diagn Investig.
2007;19(6):591–615.
14. Brunborg IM, Jonassen CM, Moldal T, Bratberg B, Lium B, Koenen F, et al.
Association of myocarditis with high viral load of porcine circovirus type 2
in several tissues in cases of fetal death and high mortality in piglets. A case
study. J Vet Diagn Investig. 2007;19(4):368–75.
15. West KH, Bystrom JM, Wojnarowicz C, Shantz N, Jacobson M, Allan GM,
et al. Myocarditis and abortion associated with intrauterine infection of
sows with porcine circovirus 2. J Vet Diagn Investig. 1999;11(6):530–2.
16. Madson DM, Ramamoorthy S, Kuster C, Pal N, Meng X-J, Halbur PG, et al.
Infectivity of porcine circovirus type 2 DNA in semen from experimentally-
infected boars. Vet Res. 2009;40(1):1.
17. Segalés J. Update on postweaning multisystemic wasting syndrome and
porcine dermatitis and nephropathy syndrome diagnostics. Journal of
Swine Health and Production. 2002;10(6):277–81.
18. Tico G, Segalés J, Martinez J. The blurred border between porcine circovirus
type 2-systemic disease and porcine respiratory disease complex. Vet
Microbiol. 2013;163(3–4):242–7.
19. Baró J, Segalés J, Martínez J. Porcine circovirus type 2 (PCV2) enteric disease:
an independent condition or part of the systemic disease? Vet Microbiol.
2015;176(1):83–7.
20. Horlen KP, Dritz SS, Nietfeld JC, Henry SC, Hesse RA, Oberst R, et al. A field
evaluation of mortality rate and growth performance in pigs vaccinated
against porcine circovirus type 2. J Am Vet Med Assoc. 2008;232(6):906–12.
21. Pejsak Z, Podgórska K, Truszczyński M, Karbowiak P, Stadejek T. Efficacy of
different protocols of vaccination against porcine circovirus type 2 (PCV2) in
a farm affected by postweaning multisystemic wasting syndrome (PMWS).
Comp Immunol Microbiol Infect Dis. 2010;33(6):e1–5.
22. Segalés J, Urniza A, Alegre A, Bru T, Crisci E, Nofrarías M, et al. A genetically
engineered chimeric vaccine against porcine circovirus type 2 (PCV2) improves
clinical, pathological and virological outcomes in postweaning multisystemic
wasting syndrome affected farms. Vaccine. 2009;27(52):7313–21.
23. Desrosiers R, Clark E, Tremblay D, Tremblay R, Polson D. Use of a one-dose
subunit vaccine to prevent losses associated with porcine circovirus type 2.
Journal of Swine Health and Production. 2009;17(3):148–54.
24. Young MG, Cunningham GL, Sanford SE. Circovirus vaccination in pigs with
subclinical porcine circovirus type 2 infection complicated by ileitis. Journal
of Swine Health and Production. 2011;19(3):175–80.
25. Fort M, Sibila M, Pérez-Martín E, Nofrarías M, Mateu E, Segalés J. One dose of a
porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old
conventional piglets elicits cell-mediated immunity and significantly reduces
PCV2 viremia in an experimental model. Vaccine. 2009;27(30):4031–7.
26. Guedes RM, Gebhart CJ, Winkelman NL, Mackie-Nuss RA. A comparative
study of an indirect fluorescent antibody test and an immunoperoxidase
monolayer assay for the diagnosis of porcine proliferative enteropathy. J Vet
Diagn Investig. 2002;14(5):420–3.
27. Hesse D, Rowland B. Circovirus vaccination decisions: Herd profiling and
next generation diagnostic testing. Allen D Leman Swine Conference. 2008:
68–71.
28. Fachinger V, Bischoff R, Jedidia SB, Saalmüller A, Elbers K. The effect of
vaccination against porcine circovirus type 2 in pigs suffering from porcine
respiratory disease complex. Vaccine. 2008;26(11):1488–99.
29. Iv R, Elbers K, Lischewski A, Woolfenden N, Strachan W. The effects of
vaccination against porcine circovirus type 2 on viraemia, viral load,
mortality and growth in a herd affected by post-weaning multisystemic
wasting syndrome. Pig Journal. 2009;62:10–26.
30. Grosse Liesner B, Orveillon F, Fachinger V, Denotte J. Efficacy of Ingelvac
CircoFLEX® in face of maternal antibodies in a field trial in France. Allen D.
Leman Swine Conference —Recent Research Reports. 2008.
31. Allan GM, Ellis JA. Porcine circoviruses: a review. J Vet Diagn Investig. 2000;
12(1):3–14.
32. Alarcon P, Rushton J, Wieland B. Cost of post-weaning multi-systemic
wasting syndrome and porcine circovirus type-2 subclinical infection in
England–an economic disease model. Preventive veterinary medicine. 2013;
110(2):88–102.
33. Segalés J. Best practice and future challenges for vaccination against
porcine circovirus type 2. Expert review of vaccines. 2015;14(3):473–87.
34. Rooke J, Bland I. The acquisition of passive immunity in the new-born
piglet. Livest Prod Sci. 2002;78(1):13–23.
35. Rodríguez-Arrioja GM, Segalés J, Calsamiglia M, Resendes AR, Balasch M,
Plana-Durán J, et al. Dynamics of porcine circovirus type 2 infection in a
herd of pigs with postweaning multisystemic wasting syndrome. Am J Vet
Res. 2002;63(3):354–7.
36. Sibila M, Calsamiglia M, Segalés J, Blanchard P, Badiella L, Le Dimna M, et al.
Use of a polymerase chain reaction assay and an ELISA to monitor porcine
circovirus type 2 infection in pigs from farms with and without
postweaning multisystemic wasting syndrome. Am J Vet Res. 2004;65(1):88–
92.
37. McIntosh KA, Harding JC, Ellis JA, Appleyard GD. Detection of porcine
circovirus type 2 viremia and seroconversion in naturally infected pigs in a
farrow-to-finish barn. Can J Vet Res. 2006;70(1):58.
38. Pomorska-Mól M, Markowska-Daniel I, Pejsak Z. Evaluation of humoral and
antigen-specific T-cell responses after vaccination of pigs against
pseudorabies in the presence of maternal antibodies. Vet Microbiol. 2010;
144(3–4):450–4.
39. Suradhat S, Damrongwatanapokin S, Thanawongnuwech R. Factors critical
for successful vaccination against classical swine fever in endemic areas. Vet
Microbiol. 2007;119(1):1–9.
40. Kitikoon P, Nilubol D, Erickson BJ, Janke BH, Hoover TC, Sornsen SA, et al.
The immune response and maternal antibody interference to a
heterologous H1N1 swine influenza virus infection following vaccination.
Vet Immunol Immunopathol. 2006;112(3–4):117–28.
41. Gava D, Souza CK, Mores TJ, Argenti LE, Streck AF, Canal CW, et al.
Dynamics of vanishing of maternally derived antibodies of ungulate
protoparvovirus 1 suggests an optimal age for gilts vaccination. Trop Anim
Health Prod. 2017;49(5):1085–8.
42. Renshaw H. Influence of antibody-mediated immune suppression on
clinical, viral, and immune responses to swine influenza infection. Am J Vet
Res. 1975;36(1):5–13.
43. Vincent AL, Ma W, Lager KM, Richt JA, Janke BH, Sandbulte MR, et al. Live
attenuated influenza vaccine provides superior protection from heterologous
infection in pigs with maternal antibodies without inducing vaccine-associated
enhanced respiratory disease. J Virol. 2012;86(19):10597–605.
44. Haake M, Palzer A, Rist B, Weissenbacher-Lang C, Fachinger V, Eggen A,
et al. Influence of age on the effectiveness of PCV2 vaccination in piglets
with high levels of maternally derived antibodies. Vet Microbiol. 2014;168(2–
4):272–80.
45. Martelli P, Saleri R, Ferrarini G, De Angelis E, Cavalli V, Benetti M, et al.
Impact of maternally derived immunity on piglets’ immune response and
protection against porcine circovirus type 2 (PCV2) after vaccination against
PCV2 at different age. BMC Vet Res. 2016;12(1):77.
46. Feng H, Segalés J, Fraile L, López-Soria S, Sibila M. Effect of high and low
levels of maternally derived antibodies on porcine circovirus type 2 (PCV2)
infection dynamics and production parameters in PCV2 vaccinated pigs
under field conditions. Vaccine. 2016;34(27):3044–50.
47. McKeown N, Opriessnig T, Thomas P, Guenette D, Elvinger F, Fenaux M,
et al. Effects of porcine circovirus type 2 (PCV2) maternal antibodies on
experimental infection of piglets with PCV2. Clin Diagn Lab Immunol. 2005;
12(11):1347–51.
48. López-Soria S, Sibila M, Nofrarías M, Calsamiglia M, Manzanilla E, Ramirez-
Mendoza H, et al. Effect of porcine circovirus type 2 (PCV2) load in serum
on average daily weight gain during the postweaning period. Vet Microbiol.
2014;174(3):296–301.
Figueras-Gourgues et al. Porcine Health Management            (2019) 5:21 Page 10 of 11
49. Declerck I, Dewulf J, Sarrazin S, Maes D. Long-term effects of colostrum
intake in piglet mortality and performance. J Anim Sci. 2016;94(4):1633–43.
50. Lopez-Rodriguez A, Dewulf J, Meyns T, Del-Pozo-Sacristán R, Andreoni C,
Goubier A, et al. Effect of sow vaccination against porcine circovirus type 2
(PCV2) on virological profiles in herds with or without PCV2 systemic
disease. The Canadian Veterinary Journal. 2016;57(6):619–28.
51. Blanchard P, Mahe D, Cariolet R, Keranflec’h A, Baudouard M, Cordioli P,
et al. Protection of swine against post-weaning multisystemic wasting
syndrome (PMWS) by porcine circovirus type 2 (PCV2) proteins. Vaccine.
2003;21(31):4565–75.
52. Nawagitgul P, Morozov I, Bolin SR, Harms PA, Sorden SD, Paul PS. Open
reading frame 2 of porcine circovirus type 2 encodes a major capsid
protein. J Gen Virol. 2000;81(9):2281–7.
53. Reddy PS, Idamakanti N, Chen Y, Whale T, Babiuk LA, Mehtali M, et al.
Replication-defective bovine adenovirus type 3 as an expression vector. J
Virol. 1999;73(11):9137–44.
54. Liu Q, Tikoo SK, Willson P. Babiuk LA. Google Patents: Methods to culture
circovirus; 2004.
55. Brunborg IM, Moldal T, Jonassen CM. Quantitation of porcine circovirus type
2 isolated from serum/plasma and tissue samples of healthy pigs and pigs
with postweaning multisystemic wasting syndrome using a TaqMan-based
real-time PCR. J Virol Methods. 2004;122(2):171–8.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Figueras-Gourgues et al. Porcine Health Management            (2019) 5:21 Page 11 of 11
